XC001 (encoberminogene rezmadenovec)
Refractory angina due to advanced coronary artery disease
Phase 2Active
Key Facts
Indication
Refractory angina due to advanced coronary artery disease
Phase
Phase 2
Status
Active
Company
About XyloCor Therapeutics
XyloCor Therapeutics is a private, pre-revenue biotech focused on addressing significant unmet needs in cardiovascular disease, specifically advanced coronary artery disease, using gene therapy. The company's lead candidate, XC001, is in Phase 2 development and aims to promote therapeutic angiogenesis. XyloCor's approach is built on foundational intellectual property from Weill Cornell and is led by a seasoned management team, positioning it to potentially offer a transformative treatment for patients with limited options.
View full company profile